Differences in the expression and function of the organic anion transporting polypeptide
(OATP) transporters contribute to interindividual variability in atorvastatin clearance …

The inhibition of hepatic uptake transporters, such as OATP1B1, on the pharmacokinetics of
atorvastatin is unknown. Here, we investigate the effect of a model hepatic transporter …

Background & Aims The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors, or statins, target liver HMG-CoA and are of proven benefit in the prevention of …

Organic anion-transporting polypeptides (OATP) 1B1 and OATP1B3 are drug transporters
mediating the active hepatic uptake of their substrates. Because they exhibit overlapping …

Rosuvastatin is an HMG-CoA reductase inhibitor and one of the most hydrophilic among the
commercially available statins. It is efficiently accumulated in the liver and excreted into the …

Atorvastatin (ATV) is primarily metabolized by CYP3A in the liver to form two active hydroxy
metabolites. Therefore, the sequential transport system governed by hepatic uptake and …

Hepatic uptake transport is often the rate‐determining step in the systemic clearance of
drugs. The ability to predict uptake clearance and to determine the contribution of individual …

Background & Aims A genome wide association study and multiple pharmacogenetic
studies have implicated the hepatic uptake transporter organic anion transporting …

Organic anion–transporting polypeptides (OATPs) mediate the liver uptake and hence
plasma clearance of a broad range of drugs. For rosuvastatin, a cholesterol-lowering drug …

Clearance of atorvastatin occurs through hepatic uptake by organic anion transporting
polypeptides (OATPs) and subsequent metabolism by cytochrome P450 (CYP) 3A4. To …